# PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

> **NCT01089998** · PHASE1 · COMPLETED · sponsor: **Life Molecular Imaging SA** · enrollment: 35 (actual)

## Conditions studied

- Diagnostic Imaging

## Interventions

- **DRUG:** BAY86-9596
- **DRUG:** BAY86-9596
- **DRUG:** BAY86-9596
- **DRUG:** Fludeoxyglucose (18F)-IBA

## Key facts

- **NCT ID:** NCT01089998
- **Lead sponsor:** Life Molecular Imaging SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089998, "PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01089998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*